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Multiresistant Gram-negative bacilli, including strains of Klebsiella pneurnoniae, Enterobacter spp, Acinetobacter 
baurnannii and Pseudornonas aeruginosa, resistant to broad spectrum beta-lactams, aminoglycosides and 
fluoroquinolones, are recovered a t  increasing frequency from patients suffering from nosocomial infections, particularly 
from those receiving intensive care. The emergence and spread of resistant pathogens to endemic and epidemic levels 
has frequently been related in time and place to the intensive use of antibiotics to which these microorganisms have 
developed resistance, notably third generation cephalosporins and fluoroquinolones. Recent investigations have 
indicated that the prevalence of resistance can be reduced by scheduled changes of empiric treatment regimens, 
involving discontinuation of intensively prescribed drugs and substitution with newly introduced antibiotics of another 
class to which the prevalent resistant strains remain susceptible. Among these drugs, penicillins-beta-lactamase 
inhibitor combinations, 'fourth generation' cephalosporins and, where little used previously, fluoroquinolones, have 
been introduced successfully in high risk units where ceftazidime-resistant strains of Kpneurnoniae, Enterobacter and 
Citrobacter spp or glycopeptide-resistant enterococci had become highly prevalent. However, these studies do not 
demonstrate a direct causal relationship between changes in prescribing practices and ecological improvements, 
because their observational design cannot be controlled. In most studies, several important factors influencing the 
dynamics of resistance were not monitored and the relative contribution of decreased emergence versus control of 
cross-transmission to the improved susceptibility rates is not clear. We propose that additional long-term studies are 
required to better track the ecological impact and to determine the optimal modalities of programmed changes of 
antibiotic prescribing as an antibiotic resistance prevention or control strategy. 
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INTRODUCTION 
The increasing antimicrobial resistance of hospital 
pathogens is today a cause of great concern to clinicians 
and microbiologists. Multiple antibiotic-resistant strains 
of Gram-negative bacilli and Gram-positive cocci are 
increasingly causing epidemic and endemic nosocomial 
infections, particularly in intensive care units [1,2]. 
Among the leading drug-resistant Gram-negative patho- 
gens are Enterobacteriaceae resistant to extended spectrum 
cephalosporins (due to production of plasmid-encoded 
extended spectrum beta-lactamase, hyperproduction of 
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chromosomal cephalosporinase, or both) and often 
cross-resistant to other major classes of antibiotics 
such as aminoglycosides and fluoroquinolones [3-41. 
Multiple-drug-resistant strains of Pseudomonas aeruginosa 
and Acinetobacter baurnannii are also increasingly en- 
countered in critically ill patients [3,4]. In Belgium, 
Enterobactev aerogenes has recently been recognized as an 
emerging multiple-drug-resistant nosocomial pathogen, 
often associated with invasive disease, including pneu- 
monia and bacteremia [4,5]. Certain clones of this 
microorganism have a remarkable propensity to spread 
to critically ill patients receiving prolonged antibiotic 
treatment and supportive care, despite specific infection 
control efforts [S]. 
THE RELATIONSHIP BEWEEN INCREASED 
ANTIBIOTIC USE AND RESISTANCE 
Resistance is emerging due to the selective pressure of 
antibiotic use which selects the bacterial subpopula- 
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tions harbouring advantageous resistance mutations or 
acquired mobile resistance determinants such as plasmids 
and transposons. Resistance becomes widespread as a 
result of dissemination of resistant clones or mobile 
genetic determinants, which are also directly favored by 
the intensity and homogeneity of antibiotic exposure 
in a patient population. The modification of the wild 
type endogenous flora by antibiotic treatment leads to 
a reduction in the colonization resistance and enhances 
the establishment of substitutive, exogenous, drug- 
resistant bacteria. Intensive use of antibiotics in the 
hospital is often associated with increasing prevalence 
of resistance [6,7]. This relationship has been explored 
by different study designs: case control studies and 
cohort studies have linked the emergence of coloniza- 
tion and infection of patients with antibiotic-resistant 
pathogens to specific risk factors, including the severity 
of underlying hsease, intensity of care, presence of in- 
dwelling devices, exposure to broad spectrum anti- 
biotics. and treatment underdosing [1,5,8-lo]. Other 
risk factors are admission to wards where resistant 
strains are epidemic or endemic and frequent exposure 
to nursing and invasive procedures [8-10]. Surveillance 
of resistance rates in hospitals has likewise revealed 
a direct correlation between the amount of broad 
spectrum antibiotics used and local prevalence of 
resistant strains during outbreaks. Such an observation 
has been reported by Rice et al, who found a strong 
correlation betweeen ward levels of ceftazidime use and 
the prevalence of clonally-related strains of Klebsiella 
pneumoniae harboring plasmid-mediated TEM-26 beta- 
lactamase during a hospital-wide outbreak [ l l ] .  
In some studies, reduction in antibiotic use has 
been followed by a reduction of resistance [6,7,11]. 
This has been achieved either by reducing total con- 
sumption by restrictive antibiotic control programs [7] 
or by a drastic shift in the type of drugs used for empiric 
therapy [6,11]. This paper will focus on the following 
questions: How to measure accurately the impact of 
antibiotic policy interventions on the prevention or 
control of antibiotic resistance in hospitals? What 
evidence is provided by recent studies on the efficacy 
of antibiotic policy in reducing epidemic or endemic 
resistance problems? 
HOW TO MONITOR THE IMPACT OF AN ANTIBIOTIC 
POLICY ON RESISTANCE RATES OF HOSPITAL 
PATHOGENS ? 
Because resistance is a complex, multifactorial eco- 
logical phenomenon, merely recording the temporal 
trends in the frequency of decreased drug susceptibility 
among large groups of microorganisms does not accu- 
rately reflect the dynamics of emergence and spread of 
resistant clones and resistance genes that interact with 
the flora of the ever-mobile hospital patient population. 
Therefore, a number of predictor variables should 
ideally be recorded to monitor the various factors 
influencing resistance prevalence, some o fwhch  can be 
controlled by medical interventions. First, the amount 
of different antimicrobial drugs used by period must be 
measured. Rather than using crude amounts in grams 
or dose units as an indicator of use, the density of 
exposure can be expressed as the number of defined 
daily doses (DDD) or average local daily admini- 
strations (DDA) per 100 patient-days. The prevalence 
of carriers of resistant strains and the importation rate 
of admitted and transferred patients colonized by 
resistant strains in each ward are important indicators 
of the initial reservoir of resistance against which any 
control intervention must be measured, especially in 
the setting of highly transmissible, endemic, multi- 
resistant strains. Lastly, the patient case-mix and bed- 
occupancy rates, as well as staffing levels and infection 
control practices, need to be monitored as factors influ- 
encing patient-to-patient transmission of resistant strains. 
Among the outcome variables that may be used to 
assess the clinical and ecological impact of the antibiotic 
policy, both prevalence and incidence indicators should 
be recorded. The prevalence of strains with decreased 
susceptibility can be determined by biologically relevant 
groups of bacteria, such as Enterobacteriaceae with in- 
ducible cephalosporinase or enterococci, but detailed 
frequencies should also be determined for bacterial 
species that may evolve into resistance phenotypes, 
either as independent entities or as communities of 
gene exchange. Moreover, molecular delineation of 
clones within each species showing a high frequency of 
resistance is required to properly interpret the dynamics 
of emergence and dissemination of resistant clones 
within and between wards [12]. Thus, the incidence of 
nosocomial acquisition of resistant strains by ward 
expressed as the number of new cases by 1000 
admissions may be checked against the incidence rate 
of imported cases admitted to the unit. The ratio of 
nosocomial cases over prevalent and imported cases 
reflects the secondary transmission rate of resistant 
clones by ward. Clearly, these detailed indicators cannot 
be assessed solely based on routine laboratory data, but 
require an integrated approach by which prospective 
epidemiological inquiries and admission screening for 
carriage of problem organisms are coordinated. 
EVIDENCE OF THE IMPACT OF HOSPITAL OR WARD 
ANTIBIOTIC POLICY INTERVENTIONS TO REVERSE 
RESISTANCE PROBLEMS 
There is more ample opportunity to ‘rotate’ antibiotics 
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to curb resistance among Gram-negative pathogens, 
against which a wider diversity of antimicrobials usually 
remains active as compared with the more limited 
alternatives to glycopeptides to treat resistant Gram- 
positive cocci. In the 1980s, studies showed that 
aminoglycoside resistance emerged and decreased in 
Gram-negative bacilli as the usage was rotated from 
gentamicin to amikacin [6]. Recent prospective studies 
reported an effective reduction of resistance by modi- 
fying usage of other classes of antibiotics within a ward 
or hospital. Tables 1 and 2 summarize the design, 
indicators used and major findings of five important 
studies of scheduled antibiotic policy changes, shifting 
from intensively prescribed antimicrobial drugs, mostly 
third generation cephalosporins, to another class of 
broad-spectrum antibiotics, such as a penicillin-beta- 
lactamase inhibitor combination, a fluoroquinolone or 
a 'fourth generation' cephalosporin. 
Each of these five studies, which used historical 
controls, concluded that the antibiotic policy change 
led to a major reduction in the prevalence of resistant 
strains that were either associated with a hospital-wide 
outbreak [ l l ]  or had become endemic in a whole 
hospital [13] and in high-risk departments [14-161. In 
three studies reporting evidence of cross-infection with 
resistant clones, infection control measures like patient 
isolation and use of barrier nursing precautions were 
either not attempted [I 11, or failed to control the spread 
after several months [13,16]. In two studies [13,14] the 
case-mix, severity of illness and exposure of patients 
to invasive procedures was compared between the base- 
line and new policy periods and, in one of these, a 
reduction in the incidence of infection was found to be 
significantly associated with the new antibiotic policy 
after controlling for these confounding factors by 
multivariable analysis [14]. In only a limited number of 
investigations was the incidence of nosocomial acqui- 
sition of resistant strains analysed and in only one were 
the dynamics of importation and transmission of resistant 
clones examined based on molecular typing (Table 2). 
In our 870-bed university hospital, the consump- 
tion of third generation cephalosporins increased 
between 1993 and 1996 from 3.5 to 4.8 x 1,000 
Defined Daily Administrations (DDA) and that of 
fluoroquinolones from 5 to 13.5 X 1,000 DDA annually, 
the latter change being in part related to an increase in 
daily dose. During that period, the rate of cefiazidime 
resistance among Enterobacteriaceae isolates recovered 
from patients admitted to the intensive care depart- 
ment, increased from 7% to 17% and the rate of 
resistance to ciprofloxacin rose from 3% to 20%. From 
mid-1994 onward, several imported clones of E. 
aerogener resistant to cefiazidime, ciprofloxacin and 
amikacin caused outbreaks in the intensive care depart- 
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Table 2 Indicators used to monitor processes and outcome of antibiotic policy intervention studles 
Antibiotic use Antibiotic resistance 
Molecular 
Reference Total amount Exposure density Case-mix Prevalence Incidence Importation typing 
11 
13 
14 
15 
16 
YES NO NO YES NO NO YES 
YES NO YES YES NO NO NO 
YES YES YES YES YES NO NO 
YES YES NO YES NO NO NO 
YES YES NO YES YES YES YES 
ments and became endemic hospital-wide despite the 
enforcement of screening and isolation of colonized 
patients [ 5 ] .  
Because these resistant strains were associated with 
sipficant nosocomial morbidity and because selection 
of resistance to carbapenems was observed during 
therapy [ 5 ] ,  a scheduled change of antibiotic policy was 
implemented [16]. Cefepinie was introduced for empiric 
therapy of infections in the intensive care department 
instead of ceftazidime and ciprofloxacin. Cefepime is a 
‘fourth generation’ cephalosporin that is known to 
possess low affinity for a majority of beta-lactamases 
and to exhibit a low capacity for selection of mutants 
of Enterobacter spp. that hyperproduce cephalosporinase 
[17,18]. It has been shown to possess clinical efficacy 
for the treatment of infections due to strains of 
Enterobacter spp with decreased susceptibility to third 
generation cephalosporins mediated by hyperproduction 
of cephalosporinase [19]. In a previous study by Mebis 
and colleagues in a hematology ward with a high rate 
of colonization by ceftazidinie-resistant Enterobacter and 
Citrobactev, replacement of ceftazidime by cefepime and 
amikacin was associated with a marked reduction of 
resistance [15]. In our evaluation, detailed monitoring 
of resistance among Gram-negative isolates recovered 
from clinical and surveillance specimens, as well as 
recording of importation and transmission rates of 
multiresistant E.  aerogenes, were performed during a 
baseline six-month period before the scheduled change 
of policy and during two consecutive six-month 
periods thereafter [16]. 
The shift in antibiotic treatment in the depart- 
ment was temporally related to a significant, three-fold 
decrease in the ceftazidime and ciprofloxacin resistance 
rates among isolates of Enterobacteriaceae. More than 
80% of the reduction in resistance rates appeared to be 
related to a decreased incidence of multiresistant E. 
aerogenes. Moreover, the ratio of new secondary cases 
per imported case of multiresistant E.  aevogenes admitted 
to the intensive care department decreased significantly. 
No increase in resistance to cefepime was observed in 
the one-year follow-up among isolates of Enterobac- 
teviaceae, although a high rate of resistance to this and 
other antipseudomonal drugs persisted during this 
period among Pseudornonas aeruginosa isolates recovered 
from patients admitted to the intensive care depart- 
ment. 
PRACTICAL IMPLICATIONS 
These studies provide encouraging results which suggesl 
that scheduled reduction of intensively used antibiotic: 
may be effective in reversing increased resistance ir 
the hospital setting and complement infection contro 
efforts to limit the spread of multiresistant clones. I 
would, therefore, seem logical to attempt regular modi. 
fication of empirical therapy prescription guideline 
either as a reactive intervention when resistance to 
particular antibiotic or class of antibiotics increase 
significantly, or even proactively with the aim c 
delaying the selection and spread of resistant strains I 
the local ecosystem of a unit or hospital. This so-calle 
‘antibiotic rotation’ or ‘antibiotic cycling’ policy remair 
to be investigated in the long term, however, before ii 
potential preventive efficacy can be established. 
In fact, as pointed out by Niederman in a luci 
editorial [20], the currently available evidence on suc 
a strategy raises more questions than it provides answer 
regarding the mechanisms of prevention or its practic 
modalities. Some questions deal with the strength an 
plausibility of the evidence supporting this approach. 1 
what proportions were the reported decreases in tk 
frequency of recovery of resistant strains due 1 
decreased emergence of resistant mutants and to contr 
of cross-colonization? Was the observed effect direct 
related to the intervention or to uncontrolled extr 
neous factors? Because natural fluctuations are observc 
in the incidence of cross-transmitted nosocorn 
pathogens, a temporal relationship does not demo. 
strate causal relationship. However, it appears extreme 
difficult to design more controlled experimental co 
ditions for this type of ecological study. CompI 
hensive, multifactorial statistical prediction models z 
probably the best available tools to estimate the preventj 
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efficacy of interventions from longitudinal studies using 
historical controls [14]. 
Secondly, if the measured beneficial effects were 
indeed caused by the intervention, was the specific 
antimicrobial drug selected responsible for the effect or 
would any other drug of a class different to that of the 
selecting agent have led to the same ecological changes? 
This question cannot be answered definitely, since 
every epidemiological setting of resistant nosocomial 
pathogens is different and such interventions cannot be 
easily stratified into comparable arms, as in a clinical 
trial. However, from the available studies, it appears that 
both beta-lactam-beta-lactamase inhibitor combinations 
and ‘fourth generation’ cephalosporins can be success- 
fully used as an alternative to third generation 
cephalosporins or fluoroquinolones in the context of 
increasingly prevalent resistant enterococci or Enterobac- 
teriaceae following intensive and prolonged use of the 
latter drugs. In one study, however, fluoroquinolones 
were also strikingly effective in a unit where they were 
previously little used (Table 1). It would therefore 
appear that the change of empiric regimen to a ‘new’ 
class of drugs may be more important than the 
particular drug regimen selected. Studies with a longer 
duration of follow-up of ecological changes in the 
local microflora are needed, to ascertain the extent of 
emergence of resistance to the newly introduced anti- 
microbial agents. The possibility of multicenter studies 
needs to be explored. 
Thirdly, if scheduled changes of antibiotic treat- 
ment regimens were indeed helpful in reversing local 
resistance problems, should they be programmed when- 
ever surveillance of the microbial flora detects a 
problem? If so, how early, and based on what threshold 
should the modification of prescription rules be 
introduced: as soon as any statistically significant change 
is detected in the colonizing flora or only when it 
becomes a major clinical problem impeding the 
expected efficacy of empiric regimens? Should they 
become a first-line control strategy, be associated with 
standard infection control precautions whenever cross- 
infection by resistant clones is documented, or should 
they be attempted only when the latter fail to control 
spread? It is likely that each institution will consider the 
practical advantages and disadvantages of these options 
on a case-by-case basis rather than embrace an all-out 
uniform strategy. 
Fourthly, should scheduled changes of antibiotic 
treatment regimens become a true preventive, rather 
than control, strategy aimed at delaying the establish- 
ment of resistant strains? It is fairly difficult, given the 
poorly understood dynamics of resistance selection and 
spread, to define biologically meaningful time intervals 
at which this ‘antibiotic crop rotation’ would be best 
effective. At any rate, it is rather impractical to m o d @  
the prescription guidelines too often, such as, for 
instance, every other quarter. Prescription guidelines 
prove difficult enough to comply with for many 
hospital physicians even when they are designed to last 
for several years. 
Whatever the ‘reactive’ or ‘pro-active’ approach 
one may attempt by periodically alternating classes of 
antimicrobials used for major indications in the treat- 
ment of infections in the hospital, it is essential to 
closely monitor the local epidemiology of resistance 
and to inform physicians about the prevalence trends 
and transmission of resistant microorganisms in their 
own units. In addition, any manipulation of the 
formulary can only be part of a more comprehensive, 
multidisciplinary system of prevention of antibiotic 
resistance by optimizing antibiotic usage and infection 
control efforts [1,20-211. 
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